Skip to main content
City Street

Projects We Work On

M & A

Overview

If you’re with a science-based company that’s contemplating a strategic deal, you need a team of lawyers who are experienced in combining their business acumen with rigorous attention to legal detail, and an appreciation for the time-sensitive nature of your opportunity.

At Faber, we have an M&A team of senior attorneys with deep experience in stock-based and asset-based acquisitions.  We also have a team of senior attorneys with deep experience in partnering transactions for technology platforms and product candidates – and their experience can be critical if your transaction will include structure (that is, earn-out contingent payments based on technology development and commercialization milestones).

Kurt, Greg, Ken, and Tim Smiling

Experience

We’ve managed hundreds of M&A transactions,  and can leverage this experience to help you design and negotiate a deal that:

  • recognizes your company’s present and future worth,

  • ensures your appropriate participation in future product development and commercialization, and

  • obtains fair treatment for your management and employees.

One or more of our senior attorneys will put our industry insights to work for you, working closely with your scientific and business leaders on all aspects of your deal ─ from preliminary discussions through due diligence, bidding and documentation.

This lean, focused staffing eliminates time-consuming handoffs, is cost-effective and provides the judgment needed for successful transactions.  And, we have the depth and breadth to support multiple parallel negotiations if you have an active auction process.

A senior lawyer will spearhead your deal. Where appropriate, they will call upon colleagues in our licensing and collaboration practice to leverage their skills and experience.

One or more of our senior attorneys will put our industry insights to work for you, working closely with your scientific and business leaders on all aspects of your deal ─ from preliminary discussions through due diligence, bidding and documentation.

Having focused staffing eliminates time-consuming handoffs, is cost-effective and provides the judgment needed for successful transactions. And, we have the depth and breadth to support multiple parallel negotiations if you have an active auction process.

Kurt Machemer

A unique understanding

In addition to traditional mergers and acquisitions, we also have the experience to appropriately and successfully use option based and staged deal structures. Our clients rely on us to provide sound business judgment, as well as legal advice, to manage or mitigate specific risks and challenges in these structures, such as a change of control or shifts in business and scientific priorities during the full deal lifecycle—and then we design, draft and negotiate appropriate provisions in the definitive agreement.

If the strategic transaction would trigger a change of control of your company, you may need help managing complicated deal processes and coordinating investment bankers, accountants, and regulatory consultants, as well as current investors. If the strategic transaction involves one of your company’s key programs, you’ll need counsel with an intrinsic understanding of your underlying business to help structure a deal that aligns with your strategic priorities.

Related Transactions

Previous Page
Next Page
DermBiont, Inc. Logo

DermBiont, Inc. + Chromaderm, Inc.

Private Company Acquisition

DermBiont acquires Chromaderm, Inc.

Press Release
DermBiont, Inc. Logo

DermBiont, Inc. + SeylanMED, Inc.

Private Company Acquisition

Faber assisted DermBiont with its acquisition of SeylanMED

Press Release
vivoPharm Pty Ltd. Logo

vivoPharm Pty Ltd. + Cancer Genetics, Inc.

Private Company Sale

Acquisition by Cancer Genetics, Inc.

+ Santhera Pharmaceuticals (Switzerland) Ltd + Idorsia Pharmaceuticals Ltd

Assignment, Amendment and Early Option Exercise Agreements

Assignment by Idorsia to Santhera of Idorsia’s option to license ReveraGen’s treatment for DMD in Phase III, and simultaneous amendment of the option agreement to provide for early exercise of Santhera’s option under revised terms

Press Release
Digital Cognition Technologies, Inc. Logo

Digital Cognition Technologies, Inc. + Linus Health

Private Company Sale

Faber assisted in the sale of Digital Cognition Technologies to Linus Health

Proteros Biostructures GmbH Logo

Proteros Biostructures GmbH + Rodin Therapeutics + Alkermes

Private Company Sale

Faber assisted Proteros biostructures GmbH with the sale of its ownership stake in Rodin Therapeutics to Alkermes

ImmunoGen, Inc. Logo

ImmunoGen, Inc. + Debiopharm International SA

Sale of Development Program

Sale of phase II antibody-drug conjugate assets from ImmunoGen for up to $55 million

Press Release
Lysosomal Therapeutics, Inc. Logo

Lysosomal Therapeutics, Inc. + Allergan plc

Exclusive Option to Aquire Company

Sale to Allergan of exclusive option to acquire LTI following completion of phase IB Clinical Trial

Codiscope, LLC Logo

Codiscope, LLC + Synopsys, Inc.

Private Company Sale

Sale of Codiscope to Synopsys

Press Release
Custom Automated Prosthetics Logo

Custom Automated Prosthetics + Henry Schein, Inc.

Private Company Sale

Sale of Custom Automated Prosthetics (digital dental laboratory supply company) to Henry Schein

Press Release
PhosImmune Logo

PhosImmune + Agenus

Private Company Sale

Sale of PhosImmune to Agenus

Phenex Pharmaceuticals AG Logo

Phenex Pharmaceuticals AG + Janssen

Research Collaboration

Research collaboration for autoimmune and chronic inflammatory disorders

Related Services

Previous Page
Next Page

This site uses cookies. Some provide anonymous analysis of how our website is used and some are essential to make the website work. Other cookies enable personalized services or social media features to be used. By using our website, you agree to the use of cookies. To find out more, please see our Privacy Policy. You can disable cookies at any time by changing your browser settings.